Merck & Co., Inc. (MRK): analysis and signal as of September 2, 2026
In short
The signal comes out weak, with a score of 1,5 for a vote of 1/1. The main reason lies in an analyst consensus target price standing below the current price and a recent advance driven by opening gaps, two elements that limit conviction despite a solid primary trend.
- Current signal
- weak (single draw, outside the three-draw protocol)
- Deterministic score
- +1.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower) | -1.5 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
Merck & Co., Inc. Benefits from a favorable sector alignment, defensive healthcare being supported by a neutral macroeconomic regime with a bullish bias of 0,55, and a beta of 0,23 sketches a defensive profile. This convergence however remains partly automatic because the fundamentals and accounting layer could not be verified. The primary trend remains solid, with 12,8 % above the 50-session moving average and 28,6 % above the 200-session moving average. The analyst consensus target price nonetheless stands below the current price, which points to zero immediate upside potential. The gap of 14,8 percentage points between overnight return and intraday return over six months further indicates an advance fed by opening gaps, structurally fragile. The Keytruda 2028 risk and the Zantac litigation lastly weigh on the profile, and the risk, sentiment and legislative layer comes out neutral because these two subjects are not settled.
Bull case
The defensive profile rests on the sector, a beta of 0,23 and a forward PER of 17,39 deemed sustainable. The pipeline of products in development, with Winrevair also called sotatercept and tulisokibart, is likely to offset the Keytruda erosion tied to the 2028 deadline. A dividend detachment on 15/09/2026 also provides a positive technical flow in the short term. This set forms the principal bullish argument of the analysis.
Bear case
Keytruda remains the structural engine and the biosimilar deadline in 2028 concentrates the downside risk over a two to three year horizon. The fundamentals and accounting layer could not be verified, the consensus target price already stands below the current price and the divergence between overnight and intraday return suggests a rise driven by overnight news, without sufficient institutional in-session support to absorb a reversal.
Scenarios
The bullish scenario, weighted 25 %, counts on a rise of about +17 % driven by extended Keytruda protection, delivery of the development pipeline and a sector rotation towards defensive healthcare. The central scenario, weighted 50 %, describes a move without strong directional conviction in a range of -3 to +3 % before T2/T3 2026 and the post-detachment catalyst. The bearish scenario, weighted 25 %, anticipates a decline of about -27 % combining earlier than expected Keytruda biosimilars, an unfavorable Zantac decision and a confirmed slowdown in post-2026 BPA.
Risks
The main risk lies in the concentration on Keytruda and the absence of fundamental verification. The thesis would be invalidated by a daily close below the 200-session moving average, which would mark the loss of the primary trend. A significant unfavorable Zantac ruling not yet provisioned would constitute a second invalidation factor. A confirmed trigger of Keytruda eligibility for future IRA waves would also degrade visibility over the 2028 horizon.
Market positioning (short sellers)
- Short interest / shares outstanding
- 0.99 %
- Days to cover
- 2.84
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| Q3 2026 results and confirmation of raised guidance | |
| SITC Conference: oncology pipeline data for Bavencio+ |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (single draw, outside the three-draw protocol) | unchanged | |
| moderate (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
Why is the signal weak despite a solid primary trend?
The primary trend shows 12,8 % above the 50-session moving average and 28,6 % above the 200-session moving average. However the analyst consensus target price sits below the current price, the rise depends mostly on opening gaps and the Keytruda 2028 and Zantac risks remain unsettled. The fundamentals layer could not be verified, which caps conviction.
What role does Keytruda play in the profile of the stock?
Keytruda remains the structural engine of the laboratory and the biosimilar deadline in 2028 concentrates the main downside risk over a two to three year horizon. The pipeline in development, with Winrevair also named sotatercept and tulisokibart, is likely to offset this future erosion. The risk layer comes out neutral precisely because this deadline and the Zantac litigation are not settled.
What does the gap between overnight and intraday return reveal?
Over six months, the gap reaches 14,8 percentage points in favor of the overnight return. The stock's advance would therefore be fed by overnight news and opening gaps, without sufficient institutional intraday support to absorb a reversal. This structure is judged fragile because it rests on a single price formation channel and not on an in-session confirmation.
Which elements would invalidate the defensive thesis?
Three elements are identified. A daily close below the 200-session moving average would mark the break of the primary trend. A significant unfavorable Zantac ruling not yet provisioned would weigh on the accounts. A confirmed trigger of Keytruda eligibility for future IRA waves would reduce visibility. These events remain unsettled at the analysis date.
Is there a near-term catalyst?
Yes. A dividend detachment is scheduled for 15/09/2026 and it provides a positive technical flow in the short term according to the analysis. The central scenario describes a move without a marked direction before the T2/T3 2026 quarters and this post-detachment catalyst. This flow does not however change the structural risks linked to the concentration on Keytruda and the Zantac litigation, which remain decisive over two to three years.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 10-Q (SEC · 10-Q)
- — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 5.07 Submission of Matters to a Vote of Security Holders (SEC · 8-K)
- — 8.01 Other Events; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 1Q26 FORM 10-Q (SEC · 10-Q)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 2, 2026; this page was completed on September 4, 2026 at 01:37 (UTC).
- Interests: no position in the stock analysed (MRK) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology